Open main menu
Home
Random
Donate
Recent changes
Special pages
Community portal
Preferences
About Stockhub
Disclaimers
Search
User menu
Talk
Contributions
Create account
Log in
Editing
Scandion Oncology
(section)
Warning:
You are not logged in. Your IP address will be publicly visible if you make any edits. If you
log in
or
create an account
, your edits will be attributed to your username, along with other benefits.
Anti-spam check. Do
not
fill this in!
== Management team == '''President and CEO: Bo Rode Hansen''' Bo Rode Hansen brings more than 20 years of international biotech and pharma business experience. Before joining Scandion Oncology, he most recently served as president and CEO at Genevant Sciences Inc. Prior to Genevant Sciences, he served as global head of Roche RNA Therapeutics and general manager of Roche Innovation Center Copenhagen. Before Roche, Bo served as executive, VP and head of drug discovery & alliances at Santaris Pharma, until the company was acquired by Roche. '''CFO: Johnny Stilou''' Johnny Stilou has held numerous executive positions as chief financial officer within the biotech and pharmaceutical industry, most recently as CFO at Amgen Research Copenhagen and Nuevolution AB (acquired by Amgen). Prior to Nuevolution, he served as CFO at Veloxis Pharmaceuticals until the company was acquired by Asahi Kasei. '''COO and head of R&D operations: Maj Hedtjarn''' Maj Hedtjärn brings more than 15 years of experience in drug discovery and development, program management and pharma alliance management from the biotech and pharmaceutical industry (Roche, Santaris Pharma and Lundbeck), where she has held numerous leadership positions within R&D. Prior to joining Scandion Oncology, she most recently served as VP and head of drug discovery, RNA Therapeutics Research at Roche Innovation Center Copenhagen. '''CMO: Alfredo Zurlo''' Alfredo is a senior pharma and biotech medical executive with more than 20 years’ experience in clinical development and medical affairs. After leaving his academic roles at the Italian University in 1999, Alfredo worked as medical advisor at the EORTC Data Center in Brussels. In 2003, he joined Roche in Basel as medical director in charge of the launch of bevacizumab (Avastin) in Europe and rest of the world for the colorectal cancer indication. Having held several senior positions at the Basel headquarters and the French affiliate over the course of the years, Alfredo left Roche and started consulting in 2011 for several pharma and biotech clients, until he became the CMO of Mologen in 2013, and later of Glycotope in 2016. {| class="wikitable" |+Shareholders !Principal shareholders !% |- |SANIONA AB |10.81 |- |Stenvang Jan |4.33 |- |Brunner Nils |3.52 |- |AVANZA PENSION |3.38 |- |NORDNET PENSIONSFORSAKRING |2.47 |- |Tang-Jespersen Christian |1.63 |- |Goeran Ofsen |1.17 |}
Summary:
Please note that all contributions to Stockhub may be edited, altered, or removed by other contributors. If you do not want your writing to be edited mercilessly, then do not submit it here.
You are also promising us that you wrote this yourself, or copied it from a public domain or similar free resource (see
Stockhub:Copyrights
for details).
Do not submit copyrighted work without permission!
Cancel
Editing help
(opens in new window)